Ibrutinib-associated osteonecrosis of the jaw
Ibrutinib is an FDA-approved first-generation oral Bruton tyrosine kinase (BTK) inhibitor that has been used in the treatment of patients with chronic lymphocytic leukemia (CLL). Ibrutinib has well-described side effects that limits its use such as, increased risk of atrial fibrillation, hypertensio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024000748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553732159930368 |
|---|---|
| author | Annu Singh Sion Na Joseph M. Huryn Cherry L. Estilo Steven Horwitz SaeHee K. Yom |
| author_facet | Annu Singh Sion Na Joseph M. Huryn Cherry L. Estilo Steven Horwitz SaeHee K. Yom |
| author_sort | Annu Singh |
| collection | DOAJ |
| description | Ibrutinib is an FDA-approved first-generation oral Bruton tyrosine kinase (BTK) inhibitor that has been used in the treatment of patients with chronic lymphocytic leukemia (CLL). Ibrutinib has well-described side effects that limits its use such as, increased risk of atrial fibrillation, hypertension, and hemorrhage. However, oral toxicity associated with ibrutinib has not been reported. This case report describes spontaneous medication related osteonecrosis of jaw (MRONJ) in a 72-year-old male patient with CLL likely following prolonged treatment with ibrutinib |
| format | Article |
| id | doaj-art-3795395c351e44af9996e74088d1c12e |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-3795395c351e44af9996e74088d1c12e2025-01-09T06:15:25ZengElsevierOral Oncology Reports2772-90602024-03-019100228Ibrutinib-associated osteonecrosis of the jawAnnu Singh0Sion Na1Joseph M. Huryn2Cherry L. Estilo3Steven Horwitz4SaeHee K. Yom5Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USADepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USADental Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USADental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USADepartment of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USACorresponding author. Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.; Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USAIbrutinib is an FDA-approved first-generation oral Bruton tyrosine kinase (BTK) inhibitor that has been used in the treatment of patients with chronic lymphocytic leukemia (CLL). Ibrutinib has well-described side effects that limits its use such as, increased risk of atrial fibrillation, hypertension, and hemorrhage. However, oral toxicity associated with ibrutinib has not been reported. This case report describes spontaneous medication related osteonecrosis of jaw (MRONJ) in a 72-year-old male patient with CLL likely following prolonged treatment with ibrutinibhttp://www.sciencedirect.com/science/article/pii/S2772906024000748IbrutinibMedication related osteonecrosis of the jawOsteonecrosisTyrosine kinase inhibitor |
| spellingShingle | Annu Singh Sion Na Joseph M. Huryn Cherry L. Estilo Steven Horwitz SaeHee K. Yom Ibrutinib-associated osteonecrosis of the jaw Oral Oncology Reports Ibrutinib Medication related osteonecrosis of the jaw Osteonecrosis Tyrosine kinase inhibitor |
| title | Ibrutinib-associated osteonecrosis of the jaw |
| title_full | Ibrutinib-associated osteonecrosis of the jaw |
| title_fullStr | Ibrutinib-associated osteonecrosis of the jaw |
| title_full_unstemmed | Ibrutinib-associated osteonecrosis of the jaw |
| title_short | Ibrutinib-associated osteonecrosis of the jaw |
| title_sort | ibrutinib associated osteonecrosis of the jaw |
| topic | Ibrutinib Medication related osteonecrosis of the jaw Osteonecrosis Tyrosine kinase inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024000748 |
| work_keys_str_mv | AT annusingh ibrutinibassociatedosteonecrosisofthejaw AT sionna ibrutinibassociatedosteonecrosisofthejaw AT josephmhuryn ibrutinibassociatedosteonecrosisofthejaw AT cherrylestilo ibrutinibassociatedosteonecrosisofthejaw AT stevenhorwitz ibrutinibassociatedosteonecrosisofthejaw AT saeheekyom ibrutinibassociatedosteonecrosisofthejaw |